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The metabolic syndrome is a multi-factorial disease of
considerable heterogeneity but is generally considered to
encompass the clustering of obesity, hypertension,
impaired glucose-tolerance and dyslipidemia. It is a major
cause of concern in modern medicine and it is a signifi-
cant risk factor for both cardio-vascular diseases (CVD)
and overall mortality and morbidity. The incidence for
metabolic syndrome increases with advancing age and
increasing adiposity. Patients with mental illnesses have a
reduced life expectancy compared with the General Popu-
lation and CVD contributes significantly to this. People
with mental illnesses often have an increased risk for CVD
because of a higher prevalence of obesity, smoking, diabe-
tes and hypertension and dyslipidemia. Additionally, they
have lifestyle factors that often contribute to the develop-
ment of a metabolic syndrome. Patients, specifically with
schizophrenia or bipolar disorders are prescribed psycho-
tropic medications that have different weight-gain liabili-
ties and differing risk of causing components of the
metabolic syndrome. Additionally, psychotropic medica-
tions may change spontaneous activity levels due to the
commonly occurring side effects of sedation and possible
Parkinsonism. More scientific and clinical research is
required to improve the understanding of fundamental
biochemical disorders underlying the metabolical syn-
drome and the central nervous system and peripheral
receptor biochemistry involved in the development of
insulin resistance. It is apparent that psychotropic medica-
tions differ in their level of inducing metabolic syndrome
and therefore the mechanisms of these psychotropic med-
ications need to be better understood, very likely on a
peripheral level of insulin resistance.
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